The Law Offices of Vincent Wong
SHAREHOLDER ALERT: GVA VAL SRPT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Monday, September 16, 2019 11:05 AM
NEW YORK, NY / ACCESSWIRE / September 16, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Granite Construction Incorporated (NYSE:GVA)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/granite-construction-incorporated-loss-submission-form?prid=3517&wire=1
Lead Plaintiff Deadline: October 15, 2019
Class Period: October 26, 2018 to August 1, 2019
Allegations against GVA include that: (1) the Company had assumed certain risks in connection with its heavy civil joint venture projects bid between 2012 and 2014; (2) there was an “untenable” imbalance of risk sharing between the Company and the joint venture project owners; (3) as a result, the Company was reasonably likely to incur additional project costs for its joint venture projects; (4) the Company was reasonably likely to incur additional costs in connection with certain project disputes; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects and prospects were materially misleading and/or lacked a reasonable basis.
Valaris plc (NYSE:VAL)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/valaris-plc-loss-submission-form?prid=3517&wire=1
Lead Plaintiff Deadline: October 21, 2019
Class Period: April 11, 2019 to July 31, 2019
Allegations against VAL include that: (i) the Company was plagued by a weak ultra-deepwater segment, massive cash usage, and significant negative cash flow; (ii) the foregoing was reasonably likely to have a material negative impact on the Company’s second quarter 2019 results; (iii) the merger leading to Valaris’s establishment could not deliver on its touted benefits; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sarepta-therapeutics-inc-loss-submission-form?prid=3517&wire=1
Lead Plaintiff Deadline: October 29, 2019
Class Period: September 6, 2017 to August 19, 2019
Allegations against SRPT include that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen’s accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong